Blockchain technology continues to evolve rapidly with scalability and efficiency as key challenges. Recursive SNARKs (Succinct Non-Interactive Arguments of Knowledge) have emerged as a breakthrough ...
Blockchain technology continues to evolve rapidly with scalability and efficiency as key challenges. Recursive SNARKs (Succinct Non-Interactive Arguments of Knowledge) have emerged as a breakthrough ...
Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.
The company laid out its restructuring plans in a regulatory document. These include a workforce reduction of around 20%. Before market open, Recursion disclosed in a tersely worded regulatory filing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results